

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sihuan Pharmaceutical Holdings Group Ltd.

四環醫藥控股集團有限公司

(incorporated in Bermuda with limited liability)

(Stock Code: 0460)

VOLUNTARY ANNOUNCEMENT NEW SPECIFICATIONS OF SKIN BOOSTER (BRAND NAME: DONGYAN) OF SIHUAN PHARMACEUTICAL APPROVED FOR LAUNCH BY NMPA

The board of directors (the “**Board**”) of Sihuan Pharmaceutical Holdings Group Ltd. (the “**Company**” or “**Sihuan Pharmaceutical**”, together with its subsidiaries, the “**Group**”) is pleased to announce that five new specifications of the Hyaluronic Acid Sodium Composite Solution for Injection (“**Skin Booster**” or the “**Product**”, brand name: Dongyan), independently developed by Meiyuan Space Biotechnology (Jilin) Co., Ltd. (the “**Meiyuan Space**”), a subsidiary of the Group, have been officially approved for launch by the National Medical Products Administration of China (the “**NMPA**”). The approval of the new specifications marks an important development following the market launch of the Product, further consolidating the Group’s product portfolio and competitiveness in the light medical aesthetics skin booster segment.

Dongyan, as the first composite solution skin booster containing L-carnosine approved in China for direct facial use, has core ingredients including Hyaluronic Acid, L-Carnosine, various amino acids, and Vitamin B2. It has multiple effects such as hydrating and moisturizing, antioxidant, anti-glycation, anti-inflammatory, and promoting collagen regeneration. It is used for injection into the dermis layer of the face, effectively improving skin dryness and dullness, meeting the needs of the public for light medical aesthetics skin rejuvenation, covering a wide range of consumer groups. Prior to this specification expansion, the approved specifications for the Product included 0.5mL/tube, 1.0mL/tube, 1.5mL/tube, 2.0mL/tube, 2.5mL/tube, 3.0mL/tube, and 5mL/box (including two 2.5mL/tube products); this time, five new specifications of 0.75mL/tube, 1.25mL/tube, 1.75mL/tube, 2.25mL/tube, and 2.75mL/tube have been approved, effectively filling the gap in the original product dosage range and forming a complete gradient and comprehensive product dosage spectrum.

Main value and significance of this specification expansion are as follows:

1. **Adapting to diverse skin needs and enrich clinical application scenarios:** The addition of new specifications fills the gap in the original product dosage range, and can be adapted to various clinical scenarios such as superficial care for delicate local areas, basic full-face treatment, and combined regeneration filling therapy. It provides clinicians with more precise dosage choices for different facial care areas, skin dullness conditions, and individual consumer tolerance differences, and can better match the personalized skin improvement needs of consumers of different age groups and skin conditions.
2. **Improving the construction of product matrix and strengthening the advantages of track synergy:** As the core essential category of light medical aesthetics, skin booster products have the traits of broad market space and outstanding user repurchase attributes. The domestic light medical aesthetics skin booster segmented market continues to develop steadily, and industry consumption and clinical demand are gradually upgrading towards standardization and personalization. With the comprehensive implementation of Dongyan's full gradient dose product matrix, the business synergy with the Group's different product categories, such as botulinum toxin, the PLLA filler, the PCL filler and golden microneedle, can be strengthened, which can be flexibly combined to form a joint anti-aging solution of "filling regeneration + skin repair". Relying on the Group's mature marketing channel network covering over 370 cities nationwide and cooperating with over 9,000 medical institutions, this will further consolidate the full category operation advantage and market competitive advantage of Meiyen Space in the light medical aesthetics segment.
3. **Assisting in the standardized and refined development of the industry:** With the continuous upgrading of domestic medical aesthetics consumption concepts, the industry's service model has gradually shifted from the traditional model to customized and differentiated individual treatment plans. The approval of the gradient dose specifications this time can provide effective reference for the specification research and product iteration of similar Skin Booster Class III medical devices in China, and help promote the high-quality and refined development of the industry.

ABOUT MEIYAN SPACE

Meiyen Space is a new type of "one-stop" medical aesthetic platform incubated by Sihuan Pharmaceutical, through the globalization layout, comprehensive and professional medical aesthetic product matrix, product research and development, registration, production and sales of an integrated structure, is dedicated to building a leading company featuring a full medical aesthetics product matrix in China by leveraging the rigour and innovation of pharmaceutical companies. Meiyen Space continues to build a complete product matrix covering the whole life cycle needs of beauty lovers through the dual-engine drive of "self-research + BD", with more than 60 products in the pipeline, covering the basic categories of light medical aesthetic, including fillers, contouring, support, optoelectronic equipment and skin management.

Meanwhile, Meiyen Space has strong independent research and development and technology transfer strength, the professional BD team and R&D team in China and abroad can quickly promote the research and development and launching of medical aesthetic products. At present, Meiyen Space has established three production bases globally, with a perfect quality management system and effective risk management for the whole life cycle of products. Its experienced medical aesthetic sales team, nationwide sales network and well developed system can quickly promote the sales of products. Most of the sales team members of Meiyen Space come from multinational medical aesthetic and pharmaceutical enterprises, with rich experience in the sales of medical aesthetic products, and work closely with dozens of agents, the sales network has covered more than 370 cities and more than 9,000 medical aesthetic institutions.

ABOUT SIHUAN PHARMACEUTICAL

Founded in 2001 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2010, Sihuan Pharmaceutical is an international medical aesthetics and pharmaceutical company led by innovation, with an independent and leading research and development technology platform, a rich global product pipeline, strong product registration capability, a full dosage form production platform with high efficiency and low cost and a mature and excellent sales system. Adhering to the overall strategic goal for the “full promotion of a two-wheel drive strategy of its medical aesthetics and biopharmaceutical businesses”, Sihuan Pharmaceutical endeavors to build itself into a leading medical aesthetics and biopharmaceutical company in China.

This announcement is being made by the Company on a voluntary basis to update the investing public on the Group’s latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, medical equipment, treatment or orally consumed product.

By order of the Board
Sihuan Pharmaceutical Holdings Group Ltd.
Dr. Che Fengsheng
Chairman and Executive Director

Hong Kong, 5 October 2026

As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong and Ms. Chen Yanling; the non-executive director of the Company is Mr. Che Yuxuan; and the independent non-executive directors of the Company are Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.